[go: up one dir, main page]

HN1999000029A - STATIN-MMP INHIBITOR COMBINATIONS. - Google Patents

STATIN-MMP INHIBITOR COMBINATIONS.

Info

Publication number
HN1999000029A
HN1999000029A HN1999000029A HN1999000029A HN1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A
Authority
HN
Honduras
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
HN1999000029A
Other languages
Spanish (es)
Inventor
Warner Lambert Company
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN1999000029A publication Critical patent/HN1999000029A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA COMBINACION DE UN COMPUESTO DE ESTATINA, QUE SE SABE QUE CAUSA UNA REDUCCION EN LOS NIVELES PLASMATICOS DE COLESTEROL LIPOPROTEINAS DE BAJA DENSIDAD (LDL), Y UN INHIBIDOR DE MMP, QUE REDUCE LA RUPTURA DE TEJIDOS CONECTIVOS. LA COMBINACION ES UTIL PARA TRATAR TRASTORNOS VASCULARES Y PREVENIR LA INSUFICIENCIA CARDIACA.THIS INVENTION REFERS TO A COMBINATION OF A STATIN COMPOUND WHICH IS KNOWN TO CAUSE A REDUCTION IN THE LOW-DENSITY CHOLESTEROL LIPOPROTEIN LEVELS (LDL), AND AN MMP INHIBITOR, WHICH REDUCES TISSUE RUPTURE. THE COMBINATION IS USEFUL TO TREAT VASCULAR DISORDERS AND PREVENT HEART FAILURE.

HN1999000029A 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS. HN1999000029A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
HN1999000029A true HN1999000029A (en) 1999-09-29

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000029A HN1999000029A (en) 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS.

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
JP2009514851A (en) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123902A (en) * 1995-11-02 2003-01-12 Warner Lambert Co PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
ES2167733T3 (en) * 1996-05-17 2002-05-16 Warner Lambert Co BIFENYLSULFONAMIDE MATRIX METALOPROTEINASE INHIBITORS.
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
WO1999047138A1 (en) 1999-09-23
MY140504A (en) 2009-12-31
ZA992106B (en) 1999-09-30
UY25436A1 (en) 2001-10-25
CO5070670A1 (en) 2001-08-28
KR20010041916A (en) 2001-05-25
EP1063991A1 (en) 2001-01-03
PE20000348A1 (en) 2000-05-22
GT199900039A (en) 2000-09-06
PA8469001A1 (en) 2002-09-17
AR018113A1 (en) 2001-10-31
NZ505994A (en) 2003-10-31
JP2002506818A (en) 2002-03-05
BR9815745A (en) 2000-11-14
SV1999000026A (en) 2000-01-18
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
AR032403A1 (en) INHIBITOR COMBINATIONS (ES) OF STEROL ABSORPTION WITH BLOOD MODIFIER (ES) TO TREAT VASCULAR TABLES
ECSP074704A (en) INHIBITOR COMBINATIONS (S) OF STEROL ABSORPTION WITH BLOOD MODIFIER (S) TO TREAT VASCULAR TABLES
MXPA03006855A (en) Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same.
ES2188285T3 (en) COMBINATIONS OF INHIBITORS OF THE TRANSPORT OF ILEAL BILIAR ACIDS AND DERIVATIVES OF NICOTINIC ACID FOR CARDIOVASCULAR INDICATIONS.
ES2176755T3 (en) USEFUL ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS.
MX9700237A (en) RETROVIRAL PROTEASE INHIBITOR COMBINATIONS.
UY25268A1 (en) INHIBITION OF LIPOPROTEIN OXIDATION
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
UY25299A1 (en) STATIN-CARBOXYALKYL ETHER COMBINATIONS
CL2004000366A1 (en) USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
PA8452701A1 (en) PROSTAGLANDIN AGONISTS
PT1140181E (en) RADIATION COMBINATION THERAPY AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA
HN1999000029A (en) STATIN-MMP INHIBITOR COMBINATIONS.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
GT199800177A (en) EFFECTIVE COMBINATION FOR THE TREATMENT OF IMPOTENCE.
ECSP088117A (en) DISINFECTING AGENT
BR0312845A (en) Tetrapropylammonium tetrathiomolybdate and related compounds for antiangiogenic therapies
AU2003296807A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
BR9713522A (en) Method of using cyclooxygenase-2 inhibitors as antiangiogenic agents.
BR0213181A (en) Cox-2 inhibitor combinations
ATE333279T1 (en) COMBINATION THERAPY TO MODULATE THE HUMAN SEXUAL RESPONSE
TR200100901T2 (en) Catheter-based method of preventing or delaying revascularization
DE60021350D1 (en) MMP-HEMMER AT BINDING WEB SUBSTANCE
GT199900037A (en) NEW HERBICIDE COMPOSITIONS.
ES2192703T3 (en) GUANIDINYLAMINE HETEROCICLIC COMPOUNDS USEFUL AS ALFA-2 ADRENOCEPTORS AGONISTS.